Skip to main content
ZJAMP Group Co., Ltd. logo

ZJAMP Group Co., Ltd. — Investor Relations & Filings

Ticker · 002758 ISIN · CNE100002029 LEI · 3003009OKT32LB5C0T64 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,563 across all filing types
Latest filing 2020-04-17 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002758

About ZJAMP Group Co., Ltd.

https://www.znjtgf.com

ZJAMP Group Co., Ltd. specializes in the comprehensive distribution and supply chain management of agricultural production materials. The company’s core operations encompass the procurement, storage, and sale of essential inputs, including chemical fertilizers such as urea, potash, and compound fertilizers, as well as pesticides, seeds, and agricultural machinery. Beyond product distribution, the organization provides integrated technical services, modern logistics solutions, and agricultural consultancy to enhance crop yields and farming efficiency. By leveraging an extensive network of distribution centers and service stations, the group facilitates the stable supply of high-quality agricultural resources. Its business model focuses on bridging the gap between manufacturers and end-users through efficient resource allocation and value-added services.

Recent filings

Filing Released Lang Actions
第四届监事会第三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Zhejiang Huatong Pharmaceutical Co., Ltd. It details the decisions made during the third meeting of the fourth Supervisory Board, including approval of the 2019 Supervisory Board work report, 2019 financial statements, profit distribution plan, annual report and its summary, use of raised funds, internal control self-evaluation report, external borrowing and guarantee authorizations, reappointment of the accounting firm, changes in business scope, amendments to the company charter, project delays, accounting policy changes, and independent director remuneration adjustments. The document repeatedly states that these resolutions need to be submitted to the 2019 Annual General Meeting for approval and references the full 2019 Annual Report and other reports being available on the company website and in newspapers. The document itself does not contain the full annual report or detailed financial statements but is a formal announcement of the Supervisory Board meeting resolutions and approvals related to the annual report and other matters. It is not the annual report itself but an announcement of meeting resolutions and approvals. Therefore, it fits best under Regulatory Filings (RNS) as a formal regulatory announcement of meeting resolutions and approvals related to the annual report and other corporate matters.
2020-04-17 Chinese
独立董事2019年度述职报告（谭国春）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2019 Annual Work Report" for Zhejiang Huatong Pharmaceutical Co., Ltd. It details the independent director's activities, attendance at board and shareholder meetings, opinions on various company matters including fundraising, accounting policy changes, and related party transactions during the 2019 fiscal year. The content focuses on the independent director's duties, opinions, and oversight rather than presenting financial statements or audit results. The document length is 2672 characters, which is relatively short and more of a report or statement by an independent director rather than a full audit or annual report. It does not contain financial data or audit opinions typical of an Audit Report (AR) or Annual Report (10-K). It is also not a regulatory filing or announcement but a detailed management-related report on board activities and governance. Therefore, the best fitting category is Board/Management Information (MANG), as it relates to board member activities and governance reporting.
2020-04-17 Chinese
关于2019年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Zhejiang Huatong Pharmaceutical Co., Ltd. regarding the storage and usage of funds raised in 2019. It includes specifics about the amounts raised through initial public offering and convertible bonds, the management and storage of these funds in special accounts, usage details, project investment changes, and compliance with regulatory requirements. The document references regulatory approvals from the China Securities Regulatory Commission and Shenzhen Stock Exchange guidelines, and it provides extensive financial data on fundraising and usage. This type of document is a specialized report on the management and use of raised capital funds, which aligns with the category of Capital/Financing Update (CAP). It is not an annual report, earnings release, or audit report, but a focused update on fundraising and capital usage.
2020-04-17 Chinese
内部控制规则落实自查表
Audit Report / Information Classification · 90% confidence The document is titled as an "内部控制规则落实自查表" which translates to "Internal Control Rules Implementation Self-Inspection Form." It contains detailed internal control checklists related to audit committee operations, information disclosure, insider trading controls, fundraising, related party transactions, external guarantees, major investments, and other important matters. The document is issued by the company's board and dated April 18, 2020. It does not contain financial statements or financial performance data, nor does it announce or attach a report. Instead, it is a detailed internal control audit or compliance checklist, which aligns with the nature of an Audit Report / Information (AR) filing, as it relates to internal audit and control results. The document length is 3578 characters, which is relatively short but contains substantive internal control information rather than a mere announcement or certification. Therefore, the best fitting category is AR (Audit Report / Information). FY 2019
2020-04-17 Chinese
华金证券股份有限公司关于公司部分募投项目延期的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from a sponsoring securities company regarding the delay of certain fundraising investment projects by Zhejiang Huatong Pharmaceutical Co., Ltd. It discusses the use of funds raised from the company's initial public offering, the reasons for project delays, and the impact on the company. It includes approvals from the board, independent directors, and supervisors, as well as the sponsor's verification opinion. The document references regulatory guidelines and approvals but does not contain financial statements or quarterly/yearly financial results. It is not an announcement of a report but a formal verification opinion related to fundraising project delays. This fits best under Capital/Financing Update (CAP) as it concerns updates on the use and management of capital raised through financing activities.
2020-04-17 Chinese
华金证券股份有限公司关于公司2019年度募集资金存放与使用情况的专项核查报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from 华金证券股份有限公司 regarding the 2019年度募集资金存放与使用情况 (2019 annual special inspection report on the deposit and use of raised funds) of 浙江华通医药股份有限公司. It includes extensive financial data on the amount of funds raised, their usage, balances, management, and compliance with regulatory requirements. The report references regulatory approvals, specific fundraising events (IPO and convertible bonds), and detailed tables showing the use of funds, changes in investment projects, and compliance with relevant securities regulations. The document is lengthy (over 12,000 characters) and contains substantive financial data and analysis related to fundraising and capital use. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and results of internal or regulatory checks related to accounting and fund usage, but is not a full Annual Report (10-K) or Interim Report (IR). It is not a simple announcement or certification, but a comprehensive special inspection report on fundraising funds usage, which fits best under AR. FY 2019
2020-04-17 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.